Proprietary Analytics
Overview of Proprietary Analytics by Deep Pharma Intelligence
Our Value Proposition
Deep Pharma Intelligence (DPI) is a strategic partner to the leading Life Science organizations, investment institutions (VC funds, investment banks), and governments across the globe -- in matters related to strategic positioning, and policy development in the areas of pharmaceutical and biotech research, and healthcare tech.
While Deep Pharma Intelligence is regularly producing open industry reports covering high-growth sectors in the Life Sciences, including artificial intelligence (AI), digital health, and new therapies, some of the more in-depth research is only available to our clients and strategic partners under the “Proprietary Analytics” category.
Our range of proprietary services includes custom consulting projects, based on the specific customer needs, as well as a collection of pre-produced “ready-to-use” proprietary reports, produced by our research team, covering general trends and specific action ideas and strategy insights related to the most promising business development prospects (e.g. new technologies, biotech startups), M&A prospects (e.g. pipeline development targets), and strategic growth ideas (trends profiling, industry overviews, etc).
Services
-
Preliminary due-diligence (business, science and technology, intellectual property (IP) profiling, freedom of operation assessment, legal assessment, etc).
-
Comprehensive due-diligence (deep business, science and technology assessment, IP and legal assessment, growth potential assessment, etc).
-
Infringement analysis of technology (e.g. If you plan to partner or invest in a data-analytics biotech, or AI-development vendors, it is essential to understand their technological assets, both in terms of innovation potential and in terms of legal protection and non-infringement risk management).
-
SWOT analysis of companies and technological sectors, competitive profiling.
-
Industry profiling and growth strategy development for top-tier companies and governments.
Proprietary Reports
There are several 40+ page reports delivering practical answers to these specific questions in order to optimize the short and long-term strategies of biopharma corporations and other institutions related to the industry, with a newly updated edition being released each quarter, incrementally increasing the precision, practicality and actionability of its technological and financial analysis.
Our reports are supported by our rapidly developing data mining engine, data visualization platform and analytics dashboards.
The value our reports can deliver:
Deep analysis of the deal-making prospects in the biotech and healthcare tech space, identification of top mini-trends and larger tendencies in innovations and technology adoption (e.g. AI, blockchain, eHealth tech, longevity biomarkers, new theraepuetics and therapies, etc.)
Practical guides for adopting various technological solutions and best practices, vendor profiling and contract research strategy building
Tangible forecasts on the 3 to 5-year horizon, providing an overview of future scenarios of the development of various technologies in the pharma industry
Analysis of key market players in the emerging and high-growth areas of the pharmaceutical and biotech industries
The parties who gain early access to these reports will have deep expertise on how their strategic agendas can be optimized in order to leverage novel research, new technologies, and emerging market opportunities, and stay competitive in a rapidly-changing technological environment, and taking into account shifting global priorities and trends.